Clément F
Schweiz Med Wochenschr. 1986 Feb 22;116(8):230-9.
Multiple myeloma comprises widely varying clinical varieties of a more or less evolutive character. Establishment of an effective therapeutic plan requires inter alia an analytical study of tumor mass (stages) and cytokinetics. Thus, "indolent", "slow" or "aggressive" myelomas have been reported. 19 consecutive symptomatic patients (12 with stage II, 6 with stage III) have been treated, with overall 5-year survival of 42%. In the light of these observations and the recent literature it appears essential to adopt a flexible therapeutic approach which allows a rapid switch from simple chemotherapy to heavy polychemotherapy when necessary, or postponement of treatment or halting of chemotherapy under selected conditions.
多发性骨髓瘤包括具有或多或少渐进性特征的广泛不同的临床类型。制定有效的治疗方案尤其需要对肿瘤肿块（分期）和细胞动力学进行分析研究。因此，已报道有“惰性”“缓慢”或“侵袭性”骨髓瘤。对19例连续有症状的患者（12例II期，6例III期）进行了治疗，5年总生存率为42%。鉴于这些观察结果和近期文献，采取一种灵活的治疗方法似乎至关重要，这种方法允许在必要时从单纯化疗迅速转向强烈的联合化疗，或在特定条件下推迟治疗或停止化疗。
